Renaissance Capital logo

Immunovant Sciences (Health Sciences Acquisitions) Priced, Nasdaq: IMVT

Blank check company formed by RTW Investments to acquire a biopharma or medical technology business (completed 12/19/2019).

Industry: SPAC

First Day Return: +2.6%

Industry: SPAC

We are a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses, which we refer to throughout this prospectus as our initial business combination. Although there is no restriction or limitation on what industry our target operates in, it is our intention to pursue prospective targets that are focused on healthcare innovation. We anticipate targeting companies domiciled in North America or Europe that are developing assets in the biopharma and medical technology sectors, which aligns with our management team’s experience in healthcare investing and drug development. At the time of preparing this prospectus, we have not identified any specific business combination, nor has anyone on our behalf initiated or engaged in any substantive discussions, formal or otherwise, related to such a transaction. Our efforts to date are limited to organizational activities related to this offering.
more less
IPO Data
IPO File Date 04/16/2019
Offer Price $10.00
Price Range $10.00 - $10.00
Offer Shares (mm) 10.0
Deal Size ($mm) $100
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 05/09/2019
Offer Price IPO Intelligence Only
Price Range IPO Intelligence Only
Offer Shares (mm) IPO Intelligence Only
Deal Size ($mm) $100
Lock-Up Date IPO Intelligence Only
Street Research IPO Intelligence Only
Underwriters
IPO Intelligence Only
Company Data
Headquarters New York, NY, United States
Founded 2018
Employees at IPO 3
Website www.rtwfunds.com

Immunovant Sciences (Health Sciences Acquisitions) (IMVT) Performance